Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Other Operating Expenses: 2019-2025

Historic Other Operating Expenses for BridgeBio Pharma (BBIO) over the last 5 years, with Sep 2025 value amounting to $6.6 million.

  • BridgeBio Pharma's Other Operating Expenses rose 997.49% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.9 million, marking a year-over-year increase of 524.54%. This contributed to the annual value of $3.9 million for FY2024, which is 58.54% up from last year.
  • Per BridgeBio Pharma's latest filing, its Other Operating Expenses stood at $6.6 million for Q3 2025, which was up 79.66% from $3.7 million recorded in Q2 2025.
  • BridgeBio Pharma's 5-year Other Operating Expenses high stood at $6.6 million for Q3 2025, and its period low was $109,000 during Q2 2021.
  • For the 3-year period, BridgeBio Pharma's Other Operating Expenses averaged around $1.7 million, with its median value being $599,000 (2023).
  • As far as peak fluctuations go, BridgeBio Pharma's Other Operating Expenses slumped by 58.28% in 2022, and later spiked by 997.49% in 2025.
  • BridgeBio Pharma's Other Operating Expenses (Quarterly) stood at $1.6 million in 2021, then plummeted by 58.28% to $647,000 in 2022, then decreased by 7.57% to $598,000 in 2023, then skyrocketed by 248.49% to $2.1 million in 2024, then skyrocketed by 997.49% to $6.6 million in 2025.
  • Its last three reported values are $6.6 million in Q3 2025, $3.7 million for Q2 2025, and $2.6 million during Q1 2025.